Autologous Endothelial Progenitor Cells Transplantation for Chronic Ischemic Stroke

• Status: Completed
• Trial end date: 2020-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Stroke is a frequently occurring and common diseases in nervous system,and most of the survivors will remain disorders of motor,sensory and cognition function.Stem cell transplantation provides a promising approach for rehabilitation. The main objective of this study is to evaluate the efficacy and safy of the transplantation of autologous endothelial progenitor cells in patients with chronic stroke.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Southern Medical University, China
• Collaborator: Second Affiliated Hospital of Guangzhou Medical University

Criteria

Inclusion Criteria:

• Aged 18-80 chronic ischemia stroke or patients

• With stroke history of more than 6 months, less than 60 months

• NIHSS (NIH stroke scale) score of 7 or more points

• Internal carotid artery territory infarction measured by MRI

• Can be hospitalized and signed informed consent

• With fewer effect by traditional post-stroke treatments or rehabilitations

Exclusion Criteria:

• Lacunar infarction

• Recurrent thrombotic diseases less than 6 months

• Hemorrhage stroke,brain tumor or MRI show the occlusion is not in the middle cerebral artery territory

• Pregnant women

• Can't tolerate the test because of other disease, such as heart failure, liver failure, renal failure, abnormal blood coagulation, AIDS, combine other tumor or special condition

• Penicillin anaphylaxis or some other drugs allergy

• Autoimmune disease

• Inaccessibility for follow up